Abstract
We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.
| Original language | English |
|---|---|
| Pages (from-to) | 313-320 |
| Number of pages | 8 |
| Journal | Neurological Sciences |
| Volume | 34 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2013 |
Fingerprint
Keywords
- Aldolase A
- Hyperkinetic movement disorders
- SERPA
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
Cite this
Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders. / Privitera, Daniela; Corti, Valeria; Alessio, Massimo; Volontè, Antonietta; Lampasona, Vito; Comi, Giancarlo; Martino, Gianvito; Franciotta, Diego; Furlan, Roberto; Fazio, Raffaella.
In: Neurological Sciences, Vol. 34, No. 3, 03.2013, p. 313-320.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders
AU - Privitera, Daniela
AU - Corti, Valeria
AU - Alessio, Massimo
AU - Volontè, Antonietta
AU - Lampasona, Vito
AU - Comi, Giancarlo
AU - Martino, Gianvito
AU - Franciotta, Diego
AU - Furlan, Roberto
AU - Fazio, Raffaella
PY - 2013/3
Y1 - 2013/3
N2 - We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.
AB - We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.
KW - Aldolase A
KW - Hyperkinetic movement disorders
KW - SERPA
UR - http://www.scopus.com/inward/record.url?scp=84879688716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879688716&partnerID=8YFLogxK
U2 - 10.1007/s10072-012-0996-y
DO - 10.1007/s10072-012-0996-y
M3 - Article
C2 - 22391679
AN - SCOPUS:84879688716
VL - 34
SP - 313
EP - 320
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 3
ER -